Sumary of COVID-19 vaccine more than 90% effective, Pfizer says:
- Krammer reports that the Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines, and that he has previously published work on influenza virus vaccines with a researchers studying a different COVID-19 vaccine, has previously consulted for Merck and Pfizer, and that his laboratory is collaborating with Pfizer on animal models of SARS-CoV-2 and with a researcher at the University of Pennsylvania on mRNA vaccines against SARS-CoV-2..
- A vaccine candidate developed by Pfizer and BioNTech was more than 90% effective in preventing COVID-19 and showed no serious safety concerns, according to an interim analysis of phase 3 clinical trial results released by the companies..
- Interim results showed a COVID-19 vaccine candidate developed by Pfizer and BioNTech was more than 90% effective..
- The analysis, which was conducted by an external and independent data monitoring committee, evaluated 94 confirmed cases of COVID-19 among more than 43,000 participants enrolled in the global trial, including more than 38,000 who have received two doses of the vaccine candidate..
- At 7 days after the second dose, the vaccine was more than 90% effective compared with placebo among participants with no prior exposure to SARS-CoV-2..
- The trial continues to enroll participants and is expected to continue through the final analysis, when a total of 164 confirmed COVID-19 cases have accrued, they said…